Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 249

1.

Vilaprisan for treating uterine fibroids.

Melis GB, Neri M, Piras B, Paoletti AM, Ajossa S, Pilloni M, Marotto MF, Corda V, Saba A, Giancane E, Mais V.

Expert Opin Investig Drugs. 2018 May;27(5):497-505. doi: 10.1080/13543784.2018.1471134. Epub 2018 May 7. Review.

PMID:
29718788
2.

Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice.

Liang B, Wu L, Xu H, Cheung CW, Fung WY, Wong SW, Wang CC.

Reprod Biol Endocrinol. 2018 Apr 3;16(1):32. doi: 10.1186/s12958-018-0347-9.

3.

Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.

Yun BS, Seong SJ, Jung YW, Kim ML, Bae HS, Kim MK, Shim SS.

Eur J Obstet Gynecol Reprod Biol. 2018 May;224:133-136. doi: 10.1016/j.ejogrb.2018.03.026. Epub 2018 Mar 17.

PMID:
29602142
4.

Two synthetic progestins and natural progesterone are responsible for most of the progestagenic activities in municipal wastewater treatment plant effluents in the Czech and Slovak republics.

Šauer P, Stará A, Golovko O, Valentová O, Bořík A, Grabic R, Kroupová HK.

Water Res. 2018 Jun 15;137:64-71. doi: 10.1016/j.watres.2018.02.065. Epub 2018 Mar 2.

PMID:
29544204
5.

Emerging treatment options for uterine fibroids.

Donnez J, Arriagada P, Donnez O, Dolmans MM.

Expert Opin Emerg Drugs. 2018 Mar;23(1):17-23. doi: 10.1080/14728214.2018.1446943. Epub 2018 Mar 12. Review.

PMID:
29486606
6.

Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs.

Badiani B, Chiumente M, Messori A.

Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:84-88. doi: 10.1016/j.ejogrb.2018.01.020. Epub 2018 Feb 3.

PMID:
29408752
7.

Non-surgical intervention for retroperitoneal lymphogenic and pulmonary metastases of a benign leiomyoma: treatment with ulipristal acetate.

Kortekaas KE, Pelikan HMP.

BMJ Case Rep. 2018 Jan 3;2018. pii: bcr-2017-222693. doi: 10.1136/bcr-2017-222693.

PMID:
29298791
8.

Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.

Ferrero S, Vellone VG, Barra F.

Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):107-116. doi: 10.1080/17425255.2018.1417389. Epub 2017 Dec 20. Review.

PMID:
29250979
9.

Fibromes utérins. L'ulipristal approuvé pour une utilisation prolongée.

Couillard K.

Perspect Infirm. 2017 Mar-Apr;14(2):57. French. No abstract available.

PMID:
29236373
10.

Preoperative medical therapy before surgery for uterine fibroids.

Lethaby A, Puscasiu L, Vollenhoven B.

Cochrane Database Syst Rev. 2017 Nov 15;11:CD000547. doi: 10.1002/14651858.CD000547.pub2. Review.

PMID:
29139105
11.

Effect of ulipristal acetate and mifepristone at emergency contraception dose on the embryo-endometrial attachment using an in vitro human trophoblastic spheroid and endometrial cell co-culture model.

Li HWR, Li YX, Li TT, Fan H, Ng EH, Yeung WS, Ho PC, Lee KF.

Hum Reprod. 2017 Dec 1;32(12):2414-2422. doi: 10.1093/humrep/dex328.

PMID:
29121217
12.

Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis.

de Milliano I, Twisk M, Ket JC, Huirne JA, Hehenkamp WJ.

PLoS One. 2017 Oct 16;12(10):e0186158. doi: 10.1371/journal.pone.0186158. eCollection 2017. Review.

13.

Sperm chemorepulsion, a supplementary mechanism to regulate fertilization.

Guidobaldi HA, Cubilla M, Moreno A, Molino MV, Bahamondes L, Giojalas LC.

Hum Reprod. 2017 Aug 1;32(8):1560-1573. doi: 10.1093/humrep/dex232.

PMID:
28854585
14.

Interventions for emergency contraception.

Shen J, Che Y, Showell E, Chen K, Cheng L.

Cochrane Database Syst Rev. 2017 Aug 2;8:CD001324. doi: 10.1002/14651858.CD001324.pub5. Review.

PMID:
28766313
15.

Progesterone-mediated angiogenic activity of endothelial progenitor cell and angiogenesis in traumatic brain injury rats were antagonized by progesterone receptor antagonist.

Yu P, Li S, Zhang Z, Wen X, Quan W, Tian Q, Gao C, Su W, Zhang J, Jiang R.

Cell Prolif. 2017 Oct;50(5). doi: 10.1111/cpr.12362. Epub 2017 Jul 28.

PMID:
28752929
16.

Progesterone receptor modulators for endometriosis.

Fu J, Song H, Zhou M, Zhu H, Wang Y, Chen H, Huang W.

Cochrane Database Syst Rev. 2017 Jul 25;7:CD009881. doi: 10.1002/14651858.CD009881.pub2. Review.

PMID:
28742263
17.

The safety of available and emerging options for emergency contraception.

Lee JK, Schwarz EB.

Expert Opin Drug Saf. 2017 Oct;16(10):1163-1171. doi: 10.1080/14740338.2017.1354985. Epub 2017 Jul 27. Review.

PMID:
28730840
18.

Selective Progesterone Receptor Modulators for the Treatment of Uterine Leiomyomas.

Safrai M, Chill HH, Reuveni Salzman A, Shushan A.

Obstet Gynecol. 2017 Aug;130(2):315-318. doi: 10.1097/AOG.0000000000002143.

PMID:
28697115
19.

[The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].

Demura TA, Revazova ZV, Kogan EA, Adamyan LV.

Arkh Patol. 2017;79(3):19-26. doi: 10.17116/patol201779319-26. Russian.

PMID:
28631712
20.

The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.

Rozenberg S, Praet J, Pazzaglia E, Gilles C, Manigart Y, Vandromme J.

Aust N Z J Obstet Gynaecol. 2017 Aug;57(4):393-399. doi: 10.1111/ajo.12641. Epub 2017 Jun 1. Review.

PMID:
28567743

Supplemental Content

Loading ...
Support Center